6:44 PM
 | 
Dec 13, 2011
 |  BC Extra  |  Clinical News

Anacor compounds meet atopic dermatitis endpoints

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) said topical twice-daily 2% AN2728 and twice-daily 1% AN2898 for six weeks each met the primary endpoint in a Phase IIa trial...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >